Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Plos One|March 26, 2013
The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platformVilija G Jokubaitis, Tim Spelman, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|July 13, 2023
Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022Steve Simpson-Yap, Duncan Maddox, Jeanette Reece, et al.
Multiple Sclerosis and Related Disorders|August 4, 2024
Longitudinal epidemiology of multiple sclerosis over 60 years in Newcastle, Australia: 1961 to 2021Steve Simpson-Yap, Vicki E Maltby, Stacey Hall, et al.
BMJ Neurology Open|July 22, 2022
Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational dataTodd A Hardy, John Parratt, Heidi Beadnall, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 13, 2020
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudyNathaniel Lizak, Suzanne Hodgkinson, Ernest Butler, et al.
Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Annals of Clinical and Translational Neurology|May 23, 2015
Predictors of disability worsening in clinically isolated syndromeVilija G Jokubaitis, Tim Spelman, Tomas Kalincik, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2015
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosisMatthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 2019
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotypeYuan Zhou, Suzi B Claflin, Jim Stankovich, et al.
Pageof 5